Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 82
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

The PP2A-B55α phosphatase is a master regulator of mitochondrial degradation and biogenesis

The PP2A-B55α phosphatase is a master regulator of mito...

 84

Gtf2i-encoded transcription factor Tfii-i regulates myelination via Sox10 and Mbp regulatory elements

Gtf2i-encoded transcription factor Tfii-i regulates mye...

 87

Precision proteogenomics reveals pan-cancer impact of germline variants

Precision proteogenomics reveals pan-cancer impact of g...

 98